Chander Celly
Schering-Plough
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Chander Celly.
Journal of Pharmacology and Experimental Therapeutics | 2007
Richard W. Chapman; Michael Minnicozzi; Chander Celly; Jonathan E. Phillips; Ted T. Kung; R. William Hipkin; Xuedong Fan; Diane Rindgen; Gregory Deno; Richard W. Bond; Waldemar Gonsiorek; M. Motasim Billah; Jay S. Fine; John A. Hey
Sch527123 [2-hydroxy-N,N-dimethyl-3-[[2-[[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]ben-zamide] is a potent, selective antagonist of the human CXCR1 and CXCR2 receptors (Gonsiorek et al., 2007). Here we describe its pharmacologic properties at rodent CXCR2 and at the CXCR1 and CXCR2 receptors in the cynomolgus monkey, as well as its in vivo activity in models demonstrating prominent pulmonary neutrophilia, goblet cell hyperplasia, and mucus production. Sch527123 bound with high affinity to the CXCR2 receptors of mouse (Kd = 0.20 nM), rat (Kd = 0.20 nM), and cynomolgus monkey (Kd = 0.08 nM) and was a potent antagonist of CXCR2-mediated chemotaxis (IC50 ∼3–6 nM). In contrast, Sch527123 bound to cynomolgus CXCR1 with lesser affinity (Kd = 41 nM) and weakly inhibited cynomolgus CXCR1-mediated chemotaxis (IC50 ∼1000 nM). Oral treatment with Sch527123 blocked pulmonary neutrophilia (ED50 = 1.2 mg/kg) and goblet cell hyperplasia (32–38% inhibition at 1–3 mg/kg) in mice following the intranasal lipopolysaccharide (LPS) administration. In rats, Sch527123 suppressed the pulmonary neutrophilia (ED50 = 1.8 mg/kg) and increase in bronchoalveolar lavage (BAL) mucin content (ED50 =<0.1 mg/kg) induced by intratracheal (i.t.) LPS. Sch527123 also suppressed the pulmonary neutrophilia (ED50 = 1.3 mg/kg), goblet cell hyperplasia (ED50 = 0.7 mg/kg), and increase in BAL mucin content (ED50 = <1 mg/kg) in rats after i.t. administration of vanadium pentoxide. In cynomolgus monkeys, Sch527123 reduced the pulmonary neutrophilia induced by repeat bronchoscopy and lavage (ED50 = 0.3 mg/kg). Therefore, Sch527123 may offer benefit for the treatment of inflammatory lung disorders in which pulmonary neutrophilia and mucus hypersecretion are important components of the underlying disease pathology.
Journal of Pharmacological and Toxicological Methods | 2001
Richard W. Chapman; Aileen House; Susan Skeans; James Lamca; Robert W. Egan; Chander Celly; John A. Hey
INTRODUCTION This study describes a method to measure the cough reflex in dogs that is simple to perform, requires no surgical intervention and can be used to profile efficacy and side-effect liabilities of antitussive drugs. METHODS Experiments were performed in propofol-anesthetized dogs in which cardiopulmonary functions were non-invasively monitored before and after the induction of cough produced by spraying 0.75 ml of distilled water into the trachea. RESULTS The magnitude of the cough response, measured by the frequency and amplitude was not different for individual dogs performed with repeated trials on different days. Treatment with the opioid antitussive drug, torbutrol (0.055-0.0055 mg/kg, s.c.) inhibited the cough frequency but not the amplitude induced by the water challenge. Furthermore, side effects of torbutrol were identified as mild respiratory depression and an anesthetic-sparing effect with propofol. DISCUSSION This method offers many distinct advantages to evaluate efficacy of antitussive drugs including the fact that no surgery is required, it takes only 15-20 min to complete an experiment, and it can be used to simultaneously profile antitussive and side effect liabilities of drugs developed for the treatment of cough.
International Archives of Allergy and Immunology | 2005
Susan Skeans; James Lamca; Aileen House; Chander Celly; John A. Hey; Richard W. Chapman
Background: Airway closure is frequently observed in human asthma. However, limited information exists on the factors that cause this condition. In this study, an allergic cynomolgus monkey model was used to characterize the condition of airway closure and assess the contribution of histamine H1 receptors to this response. Methods: Oscillatory lung mechanics, arterial blood gases during ventilation on 100% O2 and functional residual capacity (FRC) assessed by helium dilution were measured before and then 10 min and 24 h after Ascaris aerosol challenge in 12 male Ascaris-sensitive cynomolgus monkeys. The monkeys were pretreated with intravenous saline or chlorpheniramine maleate (0.3 mg/kg) in a randomized crossover design. Results: Ascaris challenge produced a large increase in airway resistance, an increase in lung tissue damping (G) that measures ventilation inhomogeneity in the lung, a reduction in arterial oxygen tension (PaO2) during ventilation on 100% O2 and a reduction in FRC. These effects were seen 10 min after the Ascaris challenge, but by 24 h, these parameters had returned close to the baseline values. Chlorpheniramine maleate (0.3 mg/kg, i.v.) produced a 12-fold shift in the histamine bronchoconstrictor dose-response curve. Pretreatment of monkeys with chlorpheniramine maleate (0.3 mg/kg, i.v.) attenuated the increase in airway resistance induced by Ascaris challenge, but had only a small effect on the increase in G and the reductions in PaO2 and FRC after antigen. Conclusions: These results demonstrate that airway closure occurs immediately after the antigen challenge in allergic cynomolgus monkeys and that histamine H1 receptors contribute very minimally to this response.
European Journal of Pharmacology | 2007
Richard W. Chapman; Aileen House; Howard Jones; Jennifer Richard; Chander Celly; Dan Prelusky; Pauline Ting; John C. Hunter; James Lamca; Jonathan E. Phillips
European Journal of Pharmacology | 2004
Aileen House; Chander Celly; Susan Skeans; James Lamca; Robert W. Egan; John A. Hey; Richard W. Chapman
Bioorganic & Medicinal Chemistry Letters | 2007
Rongze Kuang; Ho-Jane Shue; David J. Blythin; Neng-Yang Shih; Danlin Gu; Xiao Chen; John H. Schwerdt; Ling Lin; Pauline C. Ting; Xiaohong Zhu; Robert G. Aslanian; John J. Piwinski; Li Xiao; Daniel Prelusky; Ping Wu; Ji Zhang; Xiang Zhang; Chander Celly; Michael Minnicozzi; M. Motasim Billah; Peng Wang
European Journal of Pharmacology | 2004
Richard W. Chapman; Aileen House; Fei Liu; Chander Celly; Hong Mei; John A. Hey
Archive | 2006
Manuel de Lera Ruiz; Robert G. Aslanian; Michael Y. Berlin; Kevin D. Mccormick; Chander Celly
European Journal of Pharmacology | 2006
Chander Celly; Aileen House; Susan Sehring; Xiang Y. Zhang; Howard Jones; John A. Hey; Robert W. Egan; Richard W. Chapman
Journal of Pharmacological and Toxicological Methods | 2006
Jonathan E. Phillips; Natalie R. Case; Chander Celly; Richard W. Chapman; John A. Hey; Michael Minnicozzi